Tag: Theravet
TheraVet: BIOCERA-VET available for equine dental and orthopedic pathologies
By Arnaud Bivès Published on 03/13/2024 at 7:49 a.m. (Boursier.com) — TheraVet launches BIOCERA-VET Equine in countries already covered by the…
Theravet launches Biocera-Vet for horses – 03/13/2024 at 09:59
(AOF) – Theravet announces the launch of its Biocera-VET Equine product for the treatment of dental and orthopedic pathologies in horses. “Having been evaluated by equine veterinarians” in these applications…
Theravet launches Biocera-Vet for horses
(AOF) – Theravet announces the launch of its Biocera-VET Equine product for the treatment of dental and orthopedic pathologies in horses. “Having been evaluated by equine veterinarians” in these applications…
Theravet wants to accelerate on the American market
(AOF) – Theravet announces the recruitment of Brakke Consulting to support it in the development of its growth strategy on the American market. This biotechnology company specializing in osteoarticular diseases…
TheraVet mandates an American consulting firm to support it in developing its growth strategy on the US market
(Boursier.com) — TheraVet , a pioneering biotechnology company in the treatment of osteoarticular diseases in companion animals, announces the recruitment of Brakke Consulting to support it in the development of…
TheraVet: positive feedback in canine osteosarcoma – 01/04/2024 at 10:21
(CercleFinance.com) – The veterinary biotechnology company TheraVet announced on Wednesday the success of its educational webinar dedicated to canine osteosarcoma, organized in collaboration with the British Veterinary Instrumentation. The specialist…
Theravet: an equity financing line of up to 300,000 euros
(AOF) – TheraVet announces the establishment of an equity financing line. The pioneering biotechnology company in the treatment of osteoarticular diseases of companion animals specifies that this line of a…
TheraVet: funding secured until mid-2024
(CercleFinance.com) – The medical biotechnology company TheraVet ended the first half with cash of 1.7 million euros, against 3.5 million euros a year earlier, an amount sufficient to cover the…
TheraVet provides an update on its development and portfolio strategy in the first half of 2023 – 07/11/2023 at 07:30
Commercial launch of BIOCERA-VET® COMBO-CLEAN, new product reference, in MayInitiation of 3 programs in high value-added markets (Osteosarcoma, Equine and Non-Union) Dense program of scientific and clinical actions at key…
TheraVet announces a 300% increase in the number of centers participating in the dedicated osteosarcoma program since its launch six months ago – 06/15/2023 at 07:30
Growing interest in the dedicated osteosarcoma program since its official launch at the end of March 2023 with a 33% increase in the number of centers 16 participating centers in…
TheraVet: new commercial launch, the title progresses
(CercleFinance.com) – TheraVet rose on the Paris Stock Exchange on Wednesday following the announcement of the commercial launch in Europe and the United Kingdom of a first bone substitute with…
Theravet: The flagship range of veterinary biotech TheraVet opens wide doors internationally
(BFM Bourse) – The biotech TheraVet is sought after on the stock market after the signing of an exclusive distribution agreement with Vetpharma for the distribution of the Biocera-Vet product…